FIG. 4.

(a) Risk of immunologic response. (a) Odds of achieving CD4⁺ lymphocyte count >200 cells/μl after 12 months for patients with CD4⁺ lymphocyte count <200 cells/μl at HAART initiation. (b) Odds of achieving CD4⁺ lymphocyte count >350 cells/μl after 12 months for patients with CD4⁺ lymphocyte count <200 cells/μl at HAART initiation. n, number of individuals in the study cohort; aHR, adjusted hazard ratio from multivariable analyses; aOR, adjusted odds ratio from multivariable analyses; aRR, adjusted relative risk from multivariable analyses; ES, effect size of risk ratio, reported as comparing females to males; 95% CI, 95% confidence interval; Favors Males, a risk ratio less than one indicates a decreased likelihood of immunologic response for females compared to males; Favors Females, a risk ratio greater than one indicates an increased likelihood of immunologic response for females compared to males. (b) Risk of immunologic failure. (a) Odds of CD4⁺ lymphocyte count <200 cells/μl after 12 months of HAART. (b) Odds of CD4⁺ lymphocyte count <200 cells/μl after 24 months of HAART. n, number of individuals in the study cohort; uHR, univariable hazard ratio; aHR, adjusted hazard ratio from multivariable analyses; aOR, adjusted odds ratio from multivariable analyses; ES, effect size of risk ratio, reported as comparing females to males; 95% CI, 95% confidence interval; Favors Females, a risk ratio less than one indicates a decreased risk of immunologic failure for females compared to males; Favors Males, a risk ratio greater than one indicates an increased risk of immunologic failure for females compared to males.